These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6301740)

  • 1. Single-dose ceftriaxone kinetics in functionally anephric patients.
    Stoeckel K; McNamara PJ; Hoppe-Seyler G; Blumberg A; Keller E
    Clin Pharmacol Ther; 1983 May; 33(5):633-41. PubMed ID: 6301740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model.
    Stoeckel K; Koup JR
    Am J Med; 1984 Oct; 77(4C):26-32. PubMed ID: 6093514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose ceftriaxone kinetics in liver insufficiency.
    Stoeckel K; Tuerk H; Trueb V; McNamara PJ
    Clin Pharmacol Ther; 1984 Oct; 36(4):500-9. PubMed ID: 6090050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose ceftriaxone kinetics in the newborn.
    Schaad UB; Hayton WL; Stoeckel K
    Clin Pharmacol Ther; 1985 May; 37(5):522-8. PubMed ID: 3987175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age and ceftriaxone kinetics.
    Luderer JR; Patel IH; Durkin J; Schneck DW
    Clin Pharmacol Ther; 1984 Jan; 35(1):19-25. PubMed ID: 6317271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose.
    McNamara PJ; Stoeckel K; Ziegler WH
    Eur J Clin Pharmacol; 1982; 22(1):71-5. PubMed ID: 6284519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment.
    Patel IH; Sugihara JG; Weinfeld RE; Wong EG; Siemsen AW; Berman SJ
    Antimicrob Agents Chemother; 1984 Apr; 25(4):438-42. PubMed ID: 6329080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment.
    Matzke GR; Abraham PA; Halstenson CE; Keane WF
    Clin Pharmacol Ther; 1985 Jul; 38(1):31-6. PubMed ID: 4006373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Human pharmacology of ceftriaxone (author's transl)].
    Le Van Thoi J; Koumare B; Lhoste F; Soussy CJ; Duval J
    Pathol Biol (Paris); 1982 Jun; 30(6):345-7. PubMed ID: 6287386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults.
    Pollock AA; Tee PE; Patel IH; Spicehandler J; Simberkoff MS; Rahal JJ
    Antimicrob Agents Chemother; 1982 Nov; 22(5):816-23. PubMed ID: 6295268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of ceftriaxone and its relation to concentrations in extravascular compartments. Comparison with cefotaxime.
    Regamey C
    Chemotherapy; 1985; 31(2):85-94. PubMed ID: 3987394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic profile of ceftriaxone in man.
    Patel IH; Kaplan SA
    Am J Med; 1984 Oct; 77(4C):17-25. PubMed ID: 6093513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.
    Ings RM; Reeves DS; White LO; Bax RP; Bywater MJ; Holt HA
    J Pharmacokinet Biopharm; 1985 Apr; 13(2):121-42. PubMed ID: 4057054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis.
    Ti TY; Fortin L; Kreeft JH; East DS; Ogilvie RI; Somerville PJ
    Antimicrob Agents Chemother; 1984 Jan; 25(1):83-7. PubMed ID: 6322683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics.
    Stoeckel K; McNamara PJ; Brandt R; Plozza-Nottebrock H; Ziegler WH
    Clin Pharmacol Ther; 1981 May; 29(5):650-7. PubMed ID: 7053242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of ceftriaxone in subjects with renal insufficiency.
    Kowalsky SF; Echols RM; Parker MA
    Clin Pharm; 1985; 4(2):177-81. PubMed ID: 3987216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between renal function and disposition of oral cefixime.
    Dhib M; Moulin B; Leroy A; Hameau B; Godin M; Johannides R; Fillastre JP
    Eur J Clin Pharmacol; 1991; 41(6):579-83. PubMed ID: 1815970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. I. An application of pharmacokinetic model for reversible metabolism.
    Lin JH; Yeh KC; Duggan DE
    Drug Metab Dispos; 1985; 13(5):602-7. PubMed ID: 2865111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose pharmacokinetics of ceftriaxone in infants and young children.
    Schaad UB; Stoeckel K
    Antimicrob Agents Chemother; 1982 Feb; 21(2):248-53. PubMed ID: 6280597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. II. Physiological significance.
    McNamara PJ; Gibaldi M; Stoeckel K
    Eur J Clin Pharmacol; 1983; 25(3):407-12. PubMed ID: 6313380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.